U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Brist

  • PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Abecma--U.S. FDA Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels.